Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis
Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8633
DOI: 10.3390/jcm15218633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Takafumi Tanei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
Background/Objectives: Although calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) have improved migraine prevention, some patients continue to experience inadequate response or re-worsening during treatment. This study evaluated the effectiveness of add-on Kampo therapy in migraine patients receiving CGRP-mAb treatment.
Methods
This retrospective observational study included 39 migraine patients who received add-on Kampo therapy during ongoing CGRP-mAb treatment, contributing 55 treatment episodes. The primary endpoint was the change in monthly headache days (MHD) from baseline to 1 month after Kampo initiation. Secondary outcomes included migraine frequency, headache-related disability, quality of life, acute medication use, and work productivity. A responder was defined as achieving a ≥30% reduction in MHD at 1 month.
Results
The study population was highly refractory, with chronic migraine present in 79.5% of patients and medication-overuse headache in 56.4%. Among treatment episodes, 72.7% experienced re-worsening after an initial response to CGRP-mAb treatment. Median MHD was 14.0 days after CGRP-mAb treatment and subsequently increased to 16.0 days before Kampo initiation. After Kampo initiation, median MHD decreased to 10.0 days at 1 month. Significant improvements were also observed at 1 month in headache-related disability, quality of life, acute medication use, and presenteeism. The ≥30% and ≥50% responder rates at 1 month were 41.8% and 12.7%, respectively. Re-worsening after an initial CGRP-mAb response showed an exploratory association with treatment response in the Firth penalized logistic regression model.
Conclusions
Add-on Kampo therapy was associated with improvements in headache burden, quality of life, acute medication use, and work productivity in patients with inadequate response or re-worsening during CGRP-mAb treatment. These hypothesis-generating findings suggest a potential role for add-on Kampo therapy as a treatment optimization strategy and warrant confirmation in prospective controlled studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan.
- Specialized Headache Clinic, Nagoya Garden Clinic, Nagoya 451-0051, Aichi, Japan.
- Department of Neurosurgery, National Hospital Organization, Nagoya Medical Center, Nagoya 460-0001, Aichi, Japan.
ORCID-Profile: Takafumi Tanei, Satoshi Yamashita, Satoshi Maesawa, Tomotaka Ishizaki, Takahiro Suzuki, Shun Yamamoto, Ryuta Saito
Förderung
- Japanese Grant-in-Aid for Scientific Research
Zitieren
APA
Tanei, T., Yamashita, S., Maesawa, S., Ishizaki, T., Suzuki, T., Yamamoto, S., Shinoda, S., Wakabayashi, T., & Saito, R. (2026). Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis. Journal of Clinical Medicine, 15(21), 8633. https://doi.org/10.3390/jcm15218633
Vancouver
Tanei T, Yamashita S, Maesawa S, Ishizaki T, Suzuki T, Yamamoto S, et al. Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis. Journal of Clinical Medicine. 2026;15(21):8633. doi:10.3390/jcm15218633
BibTeX
@article{Tanei2026,
author = {Tanei, Takafumi and Yamashita, Satoshi and Maesawa, Satoshi and Ishizaki, Tomotaka and Suzuki, Takahiro and Yamamoto, Shun and Shinoda, Satoshi and Wakabayashi, Toshihiko and Saito, Ryuta},
title = {Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8633},
doi = {10.3390/jcm15218633}
}
EUVIMED